CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 763 enrolled
Drug / intervention
Menactra® +1 morebiological
Likely dose
Menactra® 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00862277
NCT00862277N/ACompleted
CompareCT.gov

Evaluation of the Persistence of Bactericidal Antibodies in Adolescents and Adults Who Received a Single Dose of Menactra® Four to Eight Years Earlier

Sanofi Pasteur, a Sanofi Company·observational·Posted Mar 16, 2009·Updated Apr 14, 2016

In Brief

An observational study evaluating Menactra® and Menomune® for Meningococcal Infections and Meningitis. Completed, enrolled 763 participants across 20 sites.

Detailed Summary

To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Infections, Meningitis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 16, 2009
Enrollment StartDec 1, 2008
Primary CompletionMar 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.3 years ago

Interventions

Menactra®biological

0.5 mL, Intramuscular (from a previous study)

Menomune®biological

0.5 mL, Intramuscular (from a previous study)